Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

2.625 +0.095 (+3.75%)
Streaming Delayed Price Updated: 12:31 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Diamedica Therapeutics Inc

< Previous 1 2 3 Next >
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Three (3) Stocks Under $10 That Insiders Are Buying
These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.